Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tarsa Therapeutics, Inc.

Latest From Tarsa Therapeutics, Inc.

Coronavirus Trend Helps Improve Krka’s EBIT By 85%

Slovenian firm Krka saw an increased demand for its prescription product portfolio during the quarter, which boosted group sales by more than a fifth. The company’s bottom line was a slightly more complex tale, as currency exposure in Russia wiped out significant gains in Krka’s EBIT.

Sales & Earnings Coronavirus COVID-19

Krka Finds Romanian Allegations Unjustified

Krka has denied giving its Romanian unit instructions to bribe healthcare professionals, following an internal investigation spurred by media reports of “irregularities” at the subsidiary.

Legal Issues Sales & Earnings

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.

Legal Issues Strategy

Krka Vastly Expands Research Capacity

Slovenia’s Krka has inaugurated a €55.6m research and development centre that nearly doubles its R&D capabilities and will help drive new product launches.

Strategy Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals